This project recognises that in diabetes, foot care is managed by a wide range of healthcare professionals (HCPs) who may be working with limited guidance. The aim is to develop consensus from a multidisciplinary group of experts to provide clarity on the optimal use of emollients in reducing the burden of diabetic foot ulcers. Informed by the consensus, this expert group offers a set of recommendations to support the optimal use of urea-based emollients in diabetes foot care.
A UK steering group met in January 2020 to review the current landscape of emollient use in the treatment and prevention of diabetic foot complications and identify key topics in the diabetes care pathway through discussion (Table 1).
The key topics were explored further to generate 30 consensus statements, and after discussion four more were added (Statements 14a, 15a, 16a and 17a) to add granularity regarding the presence of hyperkeratosisi. The statements were collated into a questionnaire using a 4-point Likert scale, (‘strongly disagree’, ‘tend to disagree’, ‘tend to agree’ and ‘strongly agree’). This was sent to HCPs (see Table 1 and 2) working in footcare in diabetes in the UK by an independent agency using a third-party database.
Individual scores for each statement were analysed in order to produce an arithmetic agreement score for each. Sub-analysis by role and UK region was carried out to identify any variances in agreement scores (Table 3). The threshold of agreement for consensus was predefined at 65% and ‘very high’ at ≥90%. Further rounds were considered, but after discussion, the group elected to work with the original responses.
232 UK responses were received and analysed (Figure 1).
Skin integrity on the foot impacting patients with diabetes
Loss of skin integrity on the foot can lead to severe consequences, (Statement 1, 79% and Statement 2, 93%) and maintaining skin integrity can reduce up to 80% of lower-limb amputations (Statement 3, 93%). The need for referral to specialist care is recognised (Statement 4, 91%), but it is not clear where to refer people when skin integrity is lost (Statement 5, 59%). In the UK, there is substantial variation in the interval between first assessment and arrival at the specialist team (NHS Digital, 2019). Podiatrists agreed with Statement 5 (78%, n=56), but none of the other groups achieved consensus agreement, with the lowest levels being amongst dermatologists (47%, n=53), suggesting that for those in general and non-podiatry roles, referral routes may be unclear.
People with diabetes should have timely access to a recognised and commissioned diabetes foot pathway (Statement 6, 97%) and they should know how to self-refer to this service (Statement 7, 98%). It is important that referral routes are clear and accessible, as evidence suggests that early referral is associated with better patient outcomes at 12 weeks and lower ulcer severity (NHS Digital, 2019). A specific foot protection service should be in place in the community alongside robust protocols and clear local pathways for continued and integrated care across all settings (NICE, 2019).
Treating patients with dry skin of the foot
There is clear recognition by almost all responders that dry skin is a key risk factor of foot ulceration in people with diabetes (Statement 8, 96%).
It is clear how to recognise dry skin in practice (Statement 9, 83%) and tools to grade classifications of dry skin are available; however, patients may require education to recognise signs of dry skin (American Diabetes Association, 2004; NICE, 2019).
Patient education should be comprehensive and ongoing and should cover foot health. Reduction in future risks for people with diabetes may be further improved by the inclusion of prompts for the presence of dry skin in primary care templates.
Once dry skin is detected on the foot, treatment with a urea-based emollient is more effective than non-urea-based options (Statement 10, 85%). Urea is a naturally occurring substance within the skin, which holds water within the epidermis, reduces epidermal thickness and possesses antimicrobial properties (Cork and Danby, 2009; Grether-Beck et al, 2012; Bristow, 2013).
Treating patients with hyperkeratosis of the foot
Diagnosis of hyperkeratosis is clear, and it is recognised as a risk factor for ulceration (Statement 12, 79%; Statement 11, 93%). Hyperkeratosis is associated with 26% the foot problems seen by UK podiatrists and treating this is the most common activity performed by the profession in a typical working day (Farndon, 2015). In diabetes, calluses are associated with significant pain (in severe neuropathy, the calluses are not painful) and reduction in quality of life (Farndon, 2015). The presence of callus is associated with an 11-fold risk of ulcer formation (Hamatani et al, 2016).
It is important that HCPs recognise hyperkeratosis and take appropriate action through initiation of treatment (where appropriate) and clear referral to local NHS diabetes foot services within 24 hours. Where emollient treatment is initiated, the use of urea-based emollients is considered to be a more effective treatment for hyperkeratosis than non-urea-based options by respondents.
Selecting appropriate patients for treatment with urea-based emollients
Dry skin contains up to 50% less urea than is physiologically found in healthy skin. Urea-based emollients at the proper concentration are able to compensate for the lack of urea and rehydrate the skin (Augustin et al, 2019).
In order to maintain foot skin integrity and potentially reduce the incidence of foot ulcers (and the consequences of foot ulcers), all people with diabetes should use an emollient on the feet every day (Statement 14, 81%), and where there are signs of hyperkeratosis, peripheral neuropathy or peripheral arterial disease, daily application of a urea-based emollient should be used as early as possible (Statements 14a–17a; agreement range 71–93%). Strong consensus was achieved for the use of urea-based emollients in diabetes patients with hyperkeratosis (Statement 14a, 93%). Daily frequency of application of a urea-based emollient should be based on risk — people at higher risk of ulceration may require application more than once per day.
Selecting appropriate concentration of urea-based emollients
Urea-based emollients are available in different concentrations (Statement 18, 91%) and risk factors of patients should be considered, this requires professional advice to initiate the appropriate use of urea-based emollients (Statement 19, 87%). For topical application, the urea concentration and type of vehicle used should be based on the individual condition of the skin, patient age, and the underlying dermatosis (Augustin et al, 2019). The severity of dry skin and hyperkeratosis at presentation is an important factor when selecting a urea-based emollient (Statement 20, 90%). Evidence suggests that in the treatment of hyperkeratosis, concentrations of urea-based emollients above 20% will provide keratolytic effects by unfolding cohesion proteins between corneocytes (Augustin et al, 2019).
There are cost implications if the patient is expected to purchase over the counter treatments. In order to avoid the impact of ulceration and ultimately, amputation, people with diabetes who require a urea-based emollient should have this made available via prescription at the earliest appropriate time (Statement 21, 87%) and with a urea concentration of 10–25% (above 25%, the emollient action becomes more keratolytic than hydrating; Bristow, 2016).
At each diabetes review/foot care screening, the early use of urea-based emollients should be considered by the clinic and patients referred to a commissioned diabetes foot pathway as needed.
Education surrounding diabetic foot complications
Respondents agreed strongly with all four of the consensus statements in this section (Statements 24–27; agreement range 91–95%). There is a clear need for the inclusion of the role of urea-based emollients in preventing foot ulcers (and other complications associated with diabetes) in people with diabetes by effectively treating dry skin and hyperkeratosis (Statement 24, 95%).
Whilst callus is recognised as a risk factor for foot ulceration in people with diabetes (NICE, 2019), further recommendations regarding the appropriate use of urea-based emollients, and integrating their use into local NHS care pathways, is required. In addition, patient information sources (e.g. Diabetes UK, www.nhs.uk) should be updated to include the role of urea-based emollients in helping to maintain good foot health and reduce the likelihood of an ulcer.
This is particularly important given the strong consensus that patient engagement has the greatest impact on outcomes in preventing diabetes foot complications (Statement 27, 94%) and NHS diabetes services in particular should consider how this information may be delivered to the local diabetes population. The NHS spends almost £1bn on healthcare related to foot ulceration and amputation in diabetes each year (Kerr et al, 2019). Therefore, delivering comprehensive education focused on prevention of foot ulcers may improve both outcomes for people with diabetes and reduce the significant costs of managing ulcers to the NHS. One of the ways that this could be achieved is through inclusion of foot care in diabetes patient education initiatives in the same vein as Dose Adjustment for Normal Eating (DAFNE).
Budgetary considerations surrounding diabetic foot complications
The average Clinical Commissioning Group (CCG) spends around £5.8m a year on diabetes foot problems; more than the combined cost of the four most common cancers. Reducing the prevalence of severe ulcers by one third would reduce the cost of ulcer care by around £1m a year per CCG (The College of Podiatry, 2020).
It is clear that the financial costs to the health system are under-prioritised (Statement 28, 81%). Reducing diabetic foot complications may involve additional prescribing costs of preventative treatment, but there is strong agreement that this will be lower than the costs associated with treatment of the consequences of diabetic foot complications (Statement 29, 91%).
Diabetes-related foot ulcers have a significant impact on patient outcomes and NHS resource. Foot ulcers are associated with increased rates of amputation and mortality in people with diabetes. Dry skin and hyperkeratosis are identified risk factors for foot ulcers and treating these conditions effectively may reduce occurrence of ulcers and the NHS costs associated with them.
There were high levels of agreement that people with diabetes in the presence of hyperkeratosis, peripheral neuropathy or peripheral arterial disease should be treated with daily application of a urea-based emollient, and that this treatment should be made available by prescription at the earliest appropriate time to prevent progression to ulceration.
The high levels of consensus provide a strong platform for the recommendations made by the steering group and support the need for improved management of diabetes foot concerns (particularly hyperkeratosis) at the earliest point in order to reduce the incidence and consequences of diabetes foot ulcers. These recommendations are offered in order to provide guidance on the optimal emollient treatment and prevention of diabetes-related foot complications.
There was a strong response from England (197/232) compared with other parts of the UK. The overall results were, therefore, heavily influenced by practice in England.
This consensus was focussed specifically on clinical opinion with a view to defining and recognising the issues attached to emollient use in diabetic foot care. Patient experience may help to further the understanding of the personal burden of foot ulcers.
The results of the consensus have provided a strong indication of the attitudes of clinicians to the use of urea-based emollients in the management and prevention of foot ulcers in diabetes and other complications. The steering group were able to form a strong set of recommendations to provide clarity around the role of urea-based emollients in foot ulcers in diabetes and ultimately improve outcomes for people with diabetes in both the short and long term, as well as reducing the burden of managing the complications of foot ulcers in diabetes to the NHS.
It is hoped that this consensus review may act as a springboard to raise the burden of diabetic foot care and complications in diabetes with those involved at every stage of service provision to ensure that this issue is recognised in practice and treated optimally.